GenFleet Therapeutics (Shanghai) Inc
02595
Company Profile
Business description
GenFleet Therapeutics (Shanghai) Inc is a biopharmaceutical company focused on developing novel treatment options in the fields of oncology, covering different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases. It has established a product pipeline consisting of eight product candidates with five under clinical development, including two Core Products - GFH925 and GFH375. GFH925 is an in-house discovered new drug, has been approved for commercialization in China for the treatment of advanced non-small cell lung cancer.
Contact
1206 Zhangjiang Road
Floors 2nd, 3rd, 4th, and 5th, Building 8
Shanghai) Pilot Free Trade Zone
Shanghai
CHNT: +86 2168821388
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
68
Stocks News & Analysis
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
stocks
A 5-Star US stock to buy with a near-5% yield
Undervalued by 23%, this cheap dividend stock is a top pick in its sector.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,136.50 | 33.40 | 0.37% |
| CAC 40 | 7,870.68 | 75.26 | 0.97% |
| DAX 40 | 23,739.47 | 204.64 | 0.87% |
| Dow JONES (US) | 46,247.29 | 299.97 | 0.65% |
| FTSE 100 | 9,284.83 | 70.85 | 0.77% |
| HKSE | 26,488.58 | 360.38 | 1.38% |
| NASDAQ | 22,484.07 | 99.37 | 0.44% |
| Nikkei 225 | 45,060.64 | 294.35 | -0.65% |
| NZX 50 Index | 13,139.62 | 27.89 | 0.21% |
| S&P 500 | 6,643.70 | 38.98 | 0.59% |
| S&P/ASX 200 | 8,849.00 | 38.30 | 0.43% |
| SSE Composite Index | 3,832.90 | 4.80 | 0.13% |